This session was held on September 10, 2014 with Stephen Isaacs of Aduro BioTech. During the call, Mr. Isaacs was interviewed by Mary Hesdorffer, the Meso Foundation’s executive director and experienced nurse practitioner. The focus of the interview was Aduro BioTech’s experimental therapy for malignant pleural mesothelioma, known as CRS-207. CRS-207 is a weakened form of the Listeria bacteria modified to reduce its ability to cause infections, but still able to stimulate the immune system.
Stephen Isaacs is the chairperson, president, and CEO of Aduro Biotech. In his position, he initiated the company’s current immunotherapy program based on attenuated strains of Listeria monocytogenes. He was responsible for recruiting key members of the current vaccine team with deep expertise in the biology of Listeria. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents.
